Protagonist Therapeutics announced that the U.S. Food and Drug Administration approved ICOTYDE (icotrokinra) for moderate‑to‑severe plaque psoriasis in adults and patients 12 years and older. The approval was granted on March 18, 2026, the same day the company disclosed a $50 million milestone payment that will be paid immediately upon approval.
The milestone payment, combined with a royalty structure of 6‑10 % on sales and the possibility of up to $580 million in future milestone payments under the existing partnership with Johnson & Johnson, provides a significant cash infusion. Protagonist’s cash balance was $646 million as of December 31, 2025, and the new revenue streams will help the company move toward profitability while maintaining its capital‑efficient, partnership‑driven model.
ICOTYDE is the first oral interleukin‑23 receptor antagonist, offering a convenient alternative to injectable biologics such as AbbVie’s Skyrizi and J&J’s Tremfya. Analysts project peak sales of $5.5 billion to $10 billion, reflecting the drug’s potential to capture a share of the $4 billion‑plus biologic psoriasis market. The oral route and unique mechanism also position ICOTYDE for expansion into related indications, including psoriatic arthritis, ulcerative colitis, and Crohn’s disease.
Prior to the approval, Protagonist reported Q4 2025 revenue of $7.4 million and a net loss of $44.4 million, with a trailing‑twelve‑month revenue of $46.0 million and a net loss of $130.1 million. The milestone payment and future royalties will significantly improve the company’s financial trajectory, offsetting the losses incurred during the development phase and providing runway for continued investment in its pipeline, notably rusfertide, a hepcidin mimetic for polycythemia vera.
Management emphasized the strategic importance of the approval. Jennifer Taubert, Executive Vice President of Innovative Medicine at Johnson & Johnson, said, “We’re proud to bring this game‑changing innovation to the market, marking a transformative shift in plaque psoriasis management that empowers patients and clinicians to reach their treatment goals.” CEO Dinesh Patel has repeatedly stated that Protagonist prefers to advance assets to clinical proof‑of‑concept before partnering, and the ICOTYDE approval confirms the company’s partnership‑driven approach.
The FDA approval marks a pivotal transition for Protagonist from a development‑stage company to a commercial‑stage entity. The milestone payment and royalty structure provide immediate cash and a predictable revenue stream, while the drug’s market potential and partnership with Johnson & Johnson position the company for accelerated growth and eventual profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.